TRYP THERAPEUTICS ANNOUNCES PLANS FOR PHASE 2A CLINICAL TRIAL FOR FIBROMYALGIA WITH THE UNIVERSITY OF MICHIGAN
Current treatments for fibromyalgia are often ineffective, with less than 10% of patients adhering to treatment for more than a year and 30% resorting to opioids to relieve pain.
Tryp Therapeutics (TRYP), a BC psychedelics company, is working to change this with psilocybin medicine.
This Wednesday, Tryp announced that it will be conducting a Phase 2a clinical trial to evaluate its oral formulation of synthetic psilocybin, TRYP-8802, in treating fibromyalgia, a chronic pain disorder that affects up to 8% of the population.
The trial will take place at the University of Michigan’s Chronic Pain & Fatigue Research Center and will be the world’s first trial of its kind. TRYP-8802 also shows potential to treat eating disorders, phantom limb pain, and complex regional pain syndrome by increasing neuroplasticity.